Tom O’Lenic joined Omniome in 2021 as Chief Commercial Officer. Tom has over 30 years of leadership experience in the life science and diagnostic markets. Prior to Omniome, Tom held the role of CEO of Buzzkill Labs, an early stage start-up developing a disruptive technology in the drug screening market.

As Chief Commercial Officer and General Manager at Advanced Cell Diagnostics, Tom led worldwide commercialization efforts that resulted in 50% growth for four straight years. He was instrumental in the $325M BioTechne acquisition. After the acquisition, he was promoted to General Manager of the Molecular Division at BioTechne.

Tom held executive roles at IntegenX and Molecular Devices. While at Molecular Devices, he drove commercial success leading to the $615M MDS acquisition. After the MDS acquisition, Tom was promoted to General Manager of Molecular Devices division.

Tom is presently serving on the Board of Directors of Buzzkill Labs and GenTegra. He is also on the Commercial Advisory Board at S2 Genomics.

Tom received a B.S. in Biology from the University of South Florida.